Core Viewpoint - Zhengye Biology (ZYBT) experienced a stock price increase of 4.23%, reaching $7.827 per share, with a total market capitalization of $371 million as of August 19 [1] Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company was 11.311 million RMB, showing a significant year-on-year decline of 64.04% [1] Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]
正业生物上涨4.23%，报7.827美元/股，总市值3.71亿美元